Sign inSubscribe

target directory

18f florbetaben neuraceq pet mri clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT03119558
Source recordAI-normalized

18F-Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid

Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F-Florbetaben (Neuraceq®) that targets beta amyloid can also identify cardiac amyloid deposition.

AI analysis

Indication: Cardiac Amyloidosis

Modality: small molecule

Target: 18F-Florbetaben (Neuraceq®) PET/MRI

Sponsor: Stanford University

Source URL: ClinicalTrials.gov

Source updated: Jul 17, 2019

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: 18F-Florbetaben (Neuraceq®) PET/MRI

View original source fields

Condition raw: Cardiac Amyloidosis

Condition normalized: Cardiac Amyloidosis

Modality raw: small molecule

Modality normalized: small molecule

Target raw: 18F-Florbetaben (Neuraceq®) PET/MRI

Target normalized: 18F-Florbetaben (Neuraceq®) PET/MRI

Open report